Holger Bengs

Why Patient Visits and Enrollment Estimates Are Completely Made Up (German Edition) I don’t know where to start. The conclusion might be a good introduction, though. Oncologists can’t tell you how many HER2-positive breast cancer patients visited their site last month. And if you want to know how many of them were in their 3rd line of therapy with prior PD-L1 inhibitors, they just can’t. This applies to any indication, criteria, biomarker, etc. Now you (sponsor/CRO) are asking sites to estimate the number of patients they are treating and how many of them will be eligible to be recruited. And the investigator will give you a number. Only, it’s a completely made-up number. Not because they are liars or because they want to fake the data to access the clinical research opportunity, but because you are asking them to provide a number they cannot provide. The EHR monopolies in Germany are messed up. By now, Patrick and I have had enough exposure to the UX and UI of patient records management at oncology clinics that after each demo from an investigator, we go silent, unable to exchange words. Let’s take Medistar from CompuGroup Medical Deutschland AG as an example. A company that scored $1.2 billion in revenue in 2023 with a product used by most clinical research sites. To answer the question of how many stage II breast cancer patients a site have seen in May 2024, the investigator or nurse will have to open each patient record on Medistar, scroll around, open the physician letter (a Word document), and read through it for the information. And if you want to know how many patients are, let’s say, “triple-negative” vs. HER2-positive, or if you are ambitious and looking for a specific line of therapy, you just keep reading. And if you average over 500 patients a month, you got few days of unpaid reading to do as an investigator. Sure, there is some “outsmarting the system” sites can do to have an estimate, like checking the prescription code of specific drugs. Still, that number narrows the field, mix the indications, might get you close but doesn’t give you the truth. So what can you do as an investigator? When you know you see the patient population required. No clue how many, because you work at least 12 hours a day, running from one room to the next, from one patient to the next. You would like to be part of the research. You like the IP. You like the sponsor. You write down a number. Something you think “it’s about right.” That’s all you can afford on a busy day, before the next patient enter the room, or you are asked to visit a room. - Site visit reflections #FoundersAtWork #ClinicalTrials #Oncology

36

8 Kommentare

The right-wing AfD now wants an assessment of the handling by the German government of the coronavirus pandemic. WHY?  What did we discover during the pandemic? We found out that Germany has one of the best healthcare systems in the world, with one of the highest densities of ICUs. In fact, German hospitals even welcomed many Covid19 patients from other countries. I was glad to be in Germany during the pandemic, especially if I consider how other countries fared during this crisis (e.g. Italy, Spain, France, China, Russia, the USA, even Sweden, Switzerland or the Netherlands - not always due to bad management on their side). The German population acted responsibly, overall they stuck to the rules and (except for some laggards) got vaccinated quickly. Oh, yes, keyword "vaccination": an unknown German company BioNTec developed an RNA-based vaccine in record time, and through a strategic cooperation with Pfizer, turned that into an economic success story. Overall, we should be proud. So, the whole idea of this assessment is a waste of time and money - which could better be invested in preparing for the next epidemic (birdflu perhaps?) and vaccination programs for existing diseases like measles. Perhaps the AfD could help organize such a campaign among their voters? https://lnkd.in/emNJiKzw #covid19 #coronavirus #pandemic #afd #biontec #vaccine #vaccination

1

Berlin - Exponential growth in drug-related deaths in Europe The logistical routes for the transfer of cocaine from the production site in South America to Europe are managed in the same way as normal goods transport, with producers, banks, logisticians and managers. The management hot spot is in Albania, in Tirana. The autocrat Rama has ruled the country since 2013 and legitimises himself through falsified elections. Albania has the most corrupt executive in Europe, the hot spot of money laundering in Europe and, as the BILD and security circles report, a "Rama mafia government". Rama himself also appears to be involved in the Mc Gonigall/FBI corruption scandal, together with a Russian oligarch. The pro-Western opposition in Albania is suppressed or imprisoned. As in Russia, attempts are being made to delegitimise the opposition through falsified documents and accusations of corruption. Every now and then, as in Russia, people in the administration are put in a "shop window" because of corruption, to distract the international community. It is time to send "the cavalry" to Tirana, the games of the Rama administration should be ended. Drug exports to the EU, money laundering and the deep repression of the Albanian opposition and its leaders can no longer be tolerated. https://lnkd.in/eF2vnMyz

3

2 Kommentare

🧡 🧡 🧡 ... #Crowdfunding in PIRCHE AG: I naturally seized the opportunity to invest in a #German champion of the #digital #healthcare #industry. ⬆️Nothing is without risk in life, but it also offers very good #opportunities ... investment opportunities for example. ⬇️ 👉 I have known Thomas Klein, the brain and founder behind PIRCHE, for many years; we first met at a DZ BANK AG investment forum in 2000, when I was still Managing Director at the daugher company of GoingPublic Media AG. 👉 After his career in #politics, Thomas dedicated himself to the #biotech sector more than 20 years ago, with the success of a serial entrepreneur; NOXXON Pharma N.V., ARCWAY AG ... 1️⃣ With PIRCHE, he is now well on the way to developing a #global player in the digital healthcare industry out of #Germany with a profound team of specialists, e.g. Bethany L. Dale, PhD, Matthias Niemann, etc. 2️⃣ The first #business area: #kidney #transplantation: half of all kidney transplants still fail in the first 5 to 10 years, resulting in the death of the patient, serious side effects or severe restrictions in a self-determined life. 3️⃣ PIRCHE has developped a solution with its #AI-supported #diagnostic #platform, which is already based on the experience and results of more than 250,000 patient cases in over 80 top #publications. 💪 What continues to convince me to be involved with an investment: 4️⃣ 25 #patent families with protection in #Europe, #USA and countries in #Asia 5️⃣ Top partners with ThermoFisher Scientific, Werfen and Immucor, Inc. 6️⃣ Well-known and serially successful #entrepreneurs and #investors in the #lifescience industry 💪 In the USA, seven-figure sales are already being made with top clinics 😉 The signs are good to get started in 2026 and roll out the technology globally --- not to mention the opportunities offered by the PIRCHE platform for #advanced therapies, including cell-based therapies. ❗️❗️❗️And not to forget: the increase in value, the #multiple that can be achieved with #investments before the #IPO, in the #preIPO stage. Follow Robin Binder's explanations https://lnkd.in/dM-6ukrc

36

4 Kommentare

to all my international contacts. Interested in German Cannabis - tune in to our International Briefing. Register through the link below. INTERNATIONAL BRIEFING THE FIRST MEETING WILL TAKE PLACE ON 2024-07-10 AT 20:00 (8 P.M. CET) The cannabis sector in Germany is currently experiencing a significant surge in activity following the government coalition’s decision to decriminalize and de-schedule the plant. This legislative change has created numerous opportunities for both domestic and international organizations. Industry-related events in Europe’s largest economy are witnessing record-breaking attendance. However, it is crucial for new entrants to be fully aware of the current regulations to navigate potential pitfalls. In response to this evolving landscape, the German Cannabis Business Association (BvCW – Branchenverband der Cannabiswirtschaft), the largest association of its kind in Germany, has launched a new initiative specifically for international companies seeking to enter the German market. Leveraging its unique position, the BvCW focuses on all aspects of cannabis use—medicinal, recreational, and industrial—the association will regularly disseminate information regarding recent policy changes, current opportunities and risks, and anticipated regulatory developments. “We recognize the heightened global interest in Germany at this time,” stated Dirk Heitepriem, President of the German Cannabis Business Association. “Since April 1st, a plethora of opportunities has emerged for international companies aiming to introduce products and services to the German market. We receive numerous inquiries daily from industry professionals worldwide. Our objective is to provide these companies with a platform that will guide them in identifying key opportunities while avoiding common pitfalls.” Benjamin Patock, member of the Executive Board, added, “Significant changes have taken place. Access to cannabis for medicinal purposes is now more straightforward than ever. Additionally, we are observing a substantial increase in the recreational home-growing market and the first cannabis clubs are on the horizon. However, it is important to note that some opportunities are exclusive to EU member states at this point.” The “BvCW International Briefing” will be conducted quarterly via Zoom. Participation is free of charge, subject to registration. THE FIRST MEETING WILL TAKE PLACE ON 2024-07-10 AT 20:00 (8 P.M. CET). https://lnkd.in/eMTEPQEA

48

1 Kommentar

Boris Rhein in SAT1: Hessen soll Leitstandort für laserbasierte Kernfusion werden https://buff.ly/3y1FAAQ Boris Rhein discussed on SAT1 the potential for Hessen to become a leading location for laser-based nuclear fusion. This initiative aims to position Hessen as a hub for cutting-edge fusion technology, which could revolutionize the energy sector. By investing in research and infrastructure, Hessen has the opportunity to drive innovation and attract top talent in the field. This move aligns with the global shift towards sustainable energy sources and could pave the way for significant advancements in nuclear fusion technology. #Hessen #NuclearFusion #focusedEnergy

1

#Quality #not #gender #or #quantity I don't care for quantity! I care for quality and #long-#term #results and even less for gender. And by the way being successful (somehow) doesn't mean automatically to be a #broadly #positioned #entrepreneur #teacher. Especially as an #entrepreneur (#trainer) due to competition situations now or possibly in the future you have to learn or find out what kind of #business #secrets you want or can share with your students or surrounding. Entrepreneur is a very #special #profession and should be taught and trained like that. #Doctors #and #lawyers are not educated in the backyard somehow too. As a student you have to consider what can my trainer give to me and what does he want to share with me or is he just #spying #and #using me somehow? What do you think? ENTREPRENEUR SCHOOL COLOGNE >> Wir bieten Unternehmern ein Zuhause. - Natürlich auch weiblichen Unternehmertrainerinnen. 😉

1

Thank you, Dr. Rapp, Julia Bahlmann, and FERI Cognitive Finance Institute, for challenging my perspectives on 2024's takeoff of tokenization. Your insights have been invaluable in exploring our future financial market infrastructure. The year 2024 marks an important milestone in the development of #tokenization and the transition to the #token economy. This is not least the result of the groundwork laid in 2023, which has created a solid foundation for concrete results on the blockchain. Major financial players are increasingly entering the market and driving the development of a token economy. Tokenization enables a sophisticated digital financial market infrastructure that overcomes numerous limitations of the existing economic and financial system. It goes beyond a simple technological upgrade and has the potential to fundamentally transform traditional financial markets and other economic sectors.

5

2 Kommentare